Education
About Us
Working with TipRanks
Follow Us
Cytori Cell Research Institute, Inc. (JP:3750)
:3750
RESEARCH TOOLSreports
3750 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥642.00 - ¥1,131.00
Previous CloseN/A
Volume9.00K
Average Volume (3M)11.06K
Market Cap
¥6.39B
Enterprise Value¥8.11B
Total Cash (Recent Filing)¥443.00M
Total Debt (Recent Filing)¥2.66B
Price to Earnings (P/E)55.1
Beta0.55
Next Earnings
Aug 06, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 30, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)-155.53
Shares Outstanding8,929,419
10 Day Avg. Volume3,430
30 Day Avg. Volume11,063
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
3750 FAQ
What was Cytori Cell Research Institute, Inc.’s price range in the past 12 months?
Cytori Cell Research Institute, Inc. lowest stock price was ¥642.00 and its highest was ¥1131.00 in the past 12 months.
What is Cytori Cell Research Institute, Inc.’s market cap?
Cytori Cell Research Institute, Inc.’s market cap is ¥6.39B.
When is Cytori Cell Research Institute, Inc.’s upcoming earnings report date?
Cytori Cell Research Institute, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 51 days.
How were Cytori Cell Research Institute, Inc.’s earnings last quarter?
Cytori Cell Research Institute, Inc. released its earnings results on May 15, 2025. The company reported -¥155.53 earnings per share for the quarter, missing the consensus estimate of N/A by -¥155.53.
Is Cytori Cell Research Institute, Inc. overvalued?
According to Wall Street analysts Cytori Cell Research Institute, Inc.’s price is currently Overvalued.
Does Cytori Cell Research Institute, Inc. pay dividends?
Cytori Cell Research Institute, Inc. pays a Annually dividend of ¥10 which represents an annual dividend yield of N/A. See more information on Cytori Cell Research Institute, Inc. dividends here
What is Cytori Cell Research Institute, Inc.’s EPS estimate?
Cytori Cell Research Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cytori Cell Research Institute, Inc. have?
Cytori Cell Research Institute, Inc. has 8,929,419 shares outstanding.
What happened to Cytori Cell Research Institute, Inc.’s price movement after its last earnings report?
Cytori Cell Research Institute, Inc. reported an EPS of -¥155.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.89%.
Which hedge fund is a major shareholder of Cytori Cell Research Institute, Inc.?
Currently, no hedge funds are holding shares in JP:3750
Company Description
Cytori Cell Research Institute, Inc.
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Technical Analysis
D.Western Therapeutics Institute
―
OncoTherapy Science
―
Ribomic, Inc.
―
Delta-Fly Pharma, Inc.
―
Kringle Pharma, Inc.
―